Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks
doi:10.1155/2015/648108 Yang X, Zhang Y, Huang C, Lu L, Chen J, Weng Y
A., & McNaughton, L
Philip Pape: 09:58 There was a landmark study by a French researcher named Baylard in 2016
Sage Wellness and Health and 61Five Health & Wellness both offer telehealth alongside in-person visits, so you can do intake in person and handle follow-ups remotely
GobyMeds runs on a refill-request model, so a patient who simply stops requesting refills stops the relationship